Literature DB >> 30253878

Although female patients with ankylosing spondylitis score worse on disease activity than male patients and improvement in disease activity is comparable, male patients show more radiographic progression during treatment with TNF-α inhibitors.

Boukje van der Slik1, Anneke Spoorenberg2, Freke Wink3, Reinhard Bos3, Hendrika Bootsma4, Fiona Maas4, Suzanne Arends2.   

Abstract

BACKGROUND: The clinical presentation of ankylosing spondylitis (AS) differs between genders. Our aim was to investigate differences in disease activity, disease outcome and treatment response between male and female AS patients before and after starting tumor necrosis factor (TNF)-α inhibitors in daily clinical practice.
METHODS: Patients from the Groningen Leeuwarden AS (GLAS) cohort who started TNF-α inhibitors and who had visits at baseline and after 3 months and/or 2years of follow-up were included.
RESULTS: Of 254 included AS patients, 69% were male. At baseline, female patients scored significantly higher on BASDAI, ASDAS, and tender entheses than male patients. In contrast, CRP, swollen joints, and history of extra-articular manifestations were comparable between genders. Women experienced significantly worse physical function and QoL, whereas men showed significantly more kyphosis and spinal radiographic damage. After 3 months and 2years of follow-up, all clinical assessments improved significantly, with comparable mean change scores for female and male patients; mean 2-year change in BASDAI -2.7 vs. -2.7, ASDAS -1.50 vs. -1.68, tender entheses -2.4 vs. -1.4, CRP -8 vs. -8, BASFI -2.2 vs. -2.1 and ASQoL -5 vs. -4, respectively. Radiographic progression was significantly higher in male patients. Female patients switched more frequently to another TNF-α inhibitor during 2years of follow-up (32% vs. 14%).
CONCLUSION: Although female patients experienced higher disease activity, worse physical function and quality of life, and switched TNF-α inhibitors more often, clinical improvement during treatment with TNF-α inhibitors was comparable between genders. However, male patients showed more radiographic spinal damage after 2years.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ankylosing spondylitis; Anti-TNF treatment; Disease activity; Gender differences; Quality of life; TNF-α inhibitors

Mesh:

Substances:

Year:  2018        PMID: 30253878     DOI: 10.1016/j.semarthrit.2018.07.015

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  5 in total

Review 1.  Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis.

Authors:  Rachael Stovall; Irene E van der Horst-Bruinsma; Shao-Hsien Liu; Tamara Rusman; Lianne S Gensler
Journal:  Nat Rev Rheumatol       Date:  2022-09-15       Impact factor: 32.286

Review 2.  Nonendocrine mechanisms of sex bias in rheumatic diseases.

Authors:  Nathalie C Lambert
Journal:  Nat Rev Rheumatol       Date:  2019-10-09       Impact factor: 20.543

3.  Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China.

Authors:  Xiaojian Ji; Yiwen Wang; Zhengyuan Hu; Yingpei Ma; Siliang Man; Kunpeng Li; Yanyan Wang; Jian Zhu; Jianglin Zhang; Feng Huang
Journal:  Front Pharmacol       Date:  2019-12-17       Impact factor: 5.810

4.  Gene-regulatory network analysis of ankylosing spondylitis with a single-cell chromatin accessible assay.

Authors:  Haiyan Yu; Hongwei Wu; Fengping Zheng; Chengxin Zhu; Lianghong Yin; Weier Dai; Dongzhou Liu; Donge Tang; Xiaoping Hong; Yong Dai
Journal:  Sci Rep       Date:  2020-11-10       Impact factor: 4.379

5.  Central sensitization, illness perception and obesity should be considered when interpreting disease activity in axial spondyloarthritis.

Authors:  Stan C Kieskamp; Davy Paap; Marlies J G Carbo; Freke Wink; Reinhard Bos; Hendrika Bootsma; Suzanne Arends; Anneke Spoorenberg
Journal:  Rheumatology (Oxford)       Date:  2021-10-02       Impact factor: 7.580

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.